Key Takeaways AngioDynamics expanded EU NanoKnife use to liver, pancreas, kidney and prostate tumors.ANGO will launch the LIVER-IRE Global Registry to assess real-world liver tumor outcomes.Europe drives 28% of global IRE volumes, supporting NanoKnife's multi-organ growth strategy.AngioDynamics (ANGO) recently announced expanded indications in Europe for its NanoKnife System, broadening its clinical utility in soft tissue tumor ablation. The expanded approval covers NanoKnife’s use for soft tissue ablation ...

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact on healthcare [6] Financial Performance - For the first quarter of fiscal year 2026, AngioDynamics reported net sales of $75.7 million, reflecting a year-over-year growth of 26.1% in the medical technology sector [7]

Core Insights - The global tumor ablation market is projected to grow from US$ 1.67 billion in 2024 to US$ 4.15 billion by 2032, indicating a significant growth trajectory [1]. By Technology - Radiofrequency ablation holds the largest revenue share in the tumor ablation market due to its specificity and efficiency in treating solid tumors in the liver, lung, and kidney [7]. - Microwave ablation technology is expected to experience the fastest growth, as it is effective in tissues with low electrical conductance [7]. - Cryoablation is gaining traction for treating tumors in the liver, kidneys, and prostate [7]. - High-intensity focused ultrasound (HIFU) and irreversible electroporation (IRE) are emerging modalities, with IRE being a minimally invasive outpatient procedure [7]. By Treatment Mode - Percutaneous ablation is the dominant treatment mode, offering faster recovery and minimal scarring [7]. - Surgical ablation remains a conventional and effective method for various tumor types [7]. - Laparoscopic ablation is anticipated to grow rapidly due to its precision in complex cases [7]. By Application - The liver cancer segment accounted for over 21% of the market share in 2024, driven by the high prevalence of liver cancer and a preference for minimally invasive treatments [7]. - Kidney cancer also holds a substantial market share, supported by the increasing prevalence and adoption of minimally invasive treatments [7]. - Prostate cancer and bone cancer are competing for significant shares in the tumor ablation market [8]. By End-User - Hospitals are the largest end-user segment due to their comprehensive healthcare services [14]. - Oncology centers also represent a significant share, focusing exclusively on cancer care with advanced technologies [14]. By Region - North America leads the tumor ablation market, supported by high healthcare expenditure and advanced medical technologies [14]. - Europe is the second-largest market, driven by an aging population and rising cancer prevalence [14]. - The Asia Pacific region is expected to grow the fastest, with emerging economies like China and India presenting untapped opportunities [14].

Financial Performance - AngioDynamics' total Med Device revenue grew by 62% pro forma in Q4 2025[5,9] - AngioDynamics' total Med Tech revenue grew by 220% pro forma in Q4 2025[5,9] - AngioDynamics reported pro forma Adjusted EBITDA of $34 million in Q4 2025, a $19 million improvement from Q4 FY24[5] - AngioDynamics ended the quarter with $559 million in cash and cash equivalents, up from $448 million at Feb 28, 2025[5] - AngioDynamics' total Med Tech revenue grew by 195% pro forma for FY 2025[12] - AngioDynamics' total Med Device revenue grew by 08% pro forma for FY 2025[12] Product Line Performance - Auryon sales reached $156 million in Q4 2025, a 197% year-over-year growth[16] - Total Mechanical Thrombectomy sales were $113 million in Q4 2025, a 447% year-over-year growth[5,20] - NanoKnife disposables sales grew by 55% in Q4 2025, while total NanoKnife sales decreased by 25%[5,25] Future Outlook - AngioDynamics projects full-year net sales between $305 million and $310 million for Fiscal Year 2026[27]